How to calculate clearance of highly protein-bound drugs during continuous venovenous hemofiltration demonstrated with flucloxacillin

被引:38
作者
Meyer, B
el Gendy, SA
Delle Karth, G
Locker, GJ
Heinz, G
Jaeger, W
Thalhammer, F
机构
[1] Univ Vienna, Div Infect Dis, Dept Internal Med 1, A-1090 Vienna, Austria
[2] Univ Vienna, Dept Internal Med 1, Intens Care Unit, A-1090 Vienna, Austria
[3] Univ Vienna, Dept Internal Med 2, Div Cardiol, A-1090 Vienna, Austria
[4] Univ Vienna, Inst Pharmaceut Chem, A-1090 Vienna, Austria
关键词
flucloxacillin; hemofiltration; continuous venovenous hemofiltration; pharmacokinetics; intensive care unit; protein binding; staphylococcal infections;
D O I
10.1159/000070997
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Background. Flucloxacillin is an important antimicrobial drug in the treatment of infections with Staphylococcus aureus and therefore is often used in staphylococcal infections. Furthermore, flucloxacillin has a high protein binding rate as for example ceftriaxone or teicoplanin drugs which have formerly been characterized as not being dialyzable. Methods: The pharmacokinetic parameters of 4.0 g flucloxacillin every 8 h were examined in 10 intensive care patients during continuous venovenous hemofiltration (CVVH) using a polyamide capillary hemofilter. In addition, the difficulty of calculating the hemofiltration clearance of a highly protein-bound drug is described. Results: Flucloxacillin serum levels were significantly lowered (56.9 +/- 24.0%) even though only 15% of the drug was detected in the ultrafiltrate. Elimination half-life, total body clearance and sieving coefficient were 4.9 +/- 0.7 h, 117.2 +/- 79.1 ml/min and 0.21 +/- 0.09, respectively. These discrepancies can be explained by the high protein binding of flucloxacillin, the adsorbing property of polyamide and the equation in order to calculate hemofiltration clearance. The unbound fraction of a 4.0 g flucloxacillin dosage facilitates time above the minimum inhibitory concentration (T > MIC) of 60% only for strains up to a minimum inhibitory concentration (MIC) of 0.5 mg/l. Conclusion: Based on the data of this study, we conclude that intensive care patients with staphylococcal infections on CVVH should be treated with 4.0 g flucloxacillin every 8 h which was safe and well tolerated. Moreover, further studies with highly protein-bound drugs are recommended to check the classical 'hemodialysis' equation as the standard equation in calculating the CVVH clearance of highly protein-bound drugs. Copyright (C) 2003 S. Karger AG, Basel.
引用
收藏
页码:135 / 140
页数:6
相关论文
共 19 条
[1]   ROLE OF PHARMACOKINETICS IN THE OUTCOME OF INFECTIONS [J].
DRUSANO, GL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (03) :289-297
[2]   Clearance of ceftriaxone during haemodialysis using cuprophane, haemophane and polysulfone dialysers [J].
Gabutti, L ;
TaminelliBeltraminelli, L ;
Marone, C .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 53 (02) :123-126
[3]   PHARMACOKINETICS AND BIOAVAILABILITY OF FLUCLOXACILLIN IN ELDERLY HOSPITALIZED-PATIENTS [J].
GATH, J ;
CHARLES, B ;
SAMPSON, J ;
SMITHURST, B .
JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 35 (01) :31-36
[4]   INFLUENCE OF ARTERIOVENOUS HEMOFILTRATION ON TEICOPLANIN ELIMINATION [J].
HILLAIREBUYS, D ;
PEYRIERE, H ;
LOBJOIE, E ;
BRES, J ;
OSSART, M ;
DESPAUX, E .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 40 (01) :95-97
[5]  
Joos B, 1996, NEPHROL DIAL TRANSPL, V11, P1582
[6]   Acute renal failure in multiple-organ dysfunction syndrome [J].
Kierdorf, HP ;
Seeliger, S .
KIDNEY & BLOOD PRESSURE RESEARCH, 1997, 20 (03) :164-166
[7]   Medical progress -: Staphylococcus aureus infections [J].
Lowy, FD .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (08) :520-532
[8]  
McGahee W, 2000, Semin Respir Infect, V15, P308
[9]   PENICILLINS - A CURRENT REVIEW OF THEIR CLINICAL-PHARMACOLOGY AND THERAPEUTIC USE [J].
NATHWANI, D ;
WOOD, MJ .
DRUGS, 1993, 45 (06) :866-894
[10]   PHARMACOKINETICS OF FLUCLOXACILLIN AND CLOXACILLIN IN HEALTHY SUBJECTS AND PATIENTS ON CHRONIC INTERMITTENT HEMODIALYSIS [J].
NAUTA, EH ;
MATTIE, H .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1975, 2 (02) :111-121